Skip to main content
S 2512 114th Congress Senate Health Drug safety, medical device, and laboratory regulation Drug therapy Infectious and parasitic diseases

Adding Zika Virus to the FDA Priority Review Voucher Program Act

Introduced: February 8, 2016 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 20 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 19, 2016
Signed by President.
Apr 19, 2016
Became Public Law No: 114-146.
Apr 14, 2016
Presented to President.
Apr 12, 2016
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H1602)
Apr 12, 2016
Considered under suspension of the rules. (consideration: CR H1602-1605)
Apr 12, 2016
Mrs. Brooks (IN) moved to suspend the rules and pass the bill.
Apr 12, 2016
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H1602)
Apr 12, 2016
DEBATE - The House proceeded with forty minutes of debate on S. 2512.
Apr 12, 2016
Motion to reconsider laid on the table Agreed to without objection.
Mar 25, 2016
Referred to the Subcommittee on Health.
Mar 21, 2016
Referred to the House Committee on Energy and Commerce.
Mar 21, 2016
Received in the House.
Mar 18, 2016
Message on Senate action sent to the House.
Mar 17, 2016
Passed Senate with an amendment by Unanimous Consent. (consideration: CR S1606-1607; text as passed Senate: CR S1606)
Mar 17, 2016
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(consideration: CR S1606-1607; text as passed Senate: CR S1606)
Mar 15, 2016
Placed on Senate Legislative Calendar under General Orders. Calendar No. 389.
Mar 15, 2016
Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.
Mar 9, 2016
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Feb 8, 2016
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Feb 8, 2016
Introduced in Senate
 Plain-English summary Congressional Research Service

(This measure has not been amended since it was reported to the Senate on March 15, 2016. The summary of that version is repeated here.)

Adding Zika Virus to the FDA Priority Review Voucher Program Act

(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to add Zika virus disease to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)

The bill makes a technical correction to the tropical disease list to refer to filovirus disease, a condition caused by the family of viruses that includes the Ebola virus, instead of the family of viruses.

What's happening now April 19, 2016

Became Public Law No: 114-146.

 Committees of jurisdiction 3
 Cosponsors 3
All 3 Democratic 3